Selected research
Market Analysis & Forecast
Global Tachykinin Receptor 1 Antibody Market Analysis and Forecast 2026-2032
Market perspective
The global Tachykinin Receptor 1 Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Tachykinin Receptor 1 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Tachykinin Receptor 1 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Tachykinin Receptor 1 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Tachykinin Receptor 1 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Tachykinin Receptor 1 Antibody include Merck, Boster Biological Technology, United States Biological, Santa Cruz Biotechnology, Proteintech, ProSci, NSJ Bioreagents, LSBio and GeneTex, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Tachykinin Receptor 1 Antibody, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Tachykinin Receptor 1 Antibody, also provides the revenue of main regions and countries. Of the upcoming market potential for Tachykinin Receptor 1 Antibody, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Tachykinin Receptor 1 Antibody revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Tachykinin Receptor 1 Antibody market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Tachykinin Receptor 1 Antibody revenue, projected growth trends, production technology, application and end-user industry.
Tachykinin Receptor 1 Antibody Segment by Company
Merck
Boster Biological Technology
United States Biological
Santa Cruz Biotechnology
Proteintech
ProSci
NSJ Bioreagents
LSBio
GeneTex
FineTest
Everest Biotech
Cusabio
Atlas Antibodies
Advanced Targeting Solutions
Tachykinin Receptor 1 Antibody Segment by Type
Polyclonal
Monoclonal
Tachykinin Receptor 1 Antibody Segment by Application
Western Blot
Flow Cytometry
Immunocytochemistry
Immunofluorescence
Others
Tachykinin Receptor 1 Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tachykinin Receptor 1 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tachykinin Receptor 1 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tachykinin Receptor 1 Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Tachykinin Receptor 1 Antibody in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Tachykinin Receptor 1 Antibody company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tachykinin Receptor 1 Antibody revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Polyclonal
- Monoclonal
Applications
- Western Blot
- Flow Cytometry
- Immunocytochemistry
- Immunofluorescence
- Others
Companies covered
- Merck
- Boster Biological Technology
- United States Biological
- Santa Cruz Biotechnology
- Proteintech
- ProSci
- NSJ Bioreagents
- LSBio
- GeneTex
- FineTest
- Everest Biotech
- Cusabio
- Atlas Antibodies
- Advanced Targeting Solutions
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Tachykinin Receptor 1 Antibody Market by Type
- 1.2.1 Global Tachykinin Receptor 1 Antibody Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Polyclonal
- 1.2.3 Monoclonal
- 1.3 Tachykinin Receptor 1 Antibody Market by Application
- 1.3.1 Global Tachykinin Receptor 1 Antibody Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Western Blot
- 1.3.3 Flow Cytometry
- 1.3.4 Immunocytochemistry
- 1.3.5 Immunofluorescence
- 1.3.6 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Tachykinin Receptor 1 Antibody Market Dynamics
- 2.1 Tachykinin Receptor 1 Antibody Industry Trends
- 2.2 Tachykinin Receptor 1 Antibody Industry Drivers
- 2.3 Tachykinin Receptor 1 Antibody Industry Opportunities and Challenges
- 2.4 Tachykinin Receptor 1 Antibody Industry Restraints
3 Global Growth Perspective
- 3.1 Global Tachykinin Receptor 1 Antibody Market Perspective (2021-2032)
- 3.2 Global Tachykinin Receptor 1 Antibody Growth Trends by Region
- 3.2.1 Global Tachykinin Receptor 1 Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Tachykinin Receptor 1 Antibody Market Size by Region (2021-2026)
- 3.2.3 Global Tachykinin Receptor 1 Antibody Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Tachykinin Receptor 1 Antibody Revenue by Players
- 4.1.1 Global Tachykinin Receptor 1 Antibody Revenue by Players (2021-2026)
- 4.1.2 Global Tachykinin Receptor 1 Antibody Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Tachykinin Receptor 1 Antibody Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Tachykinin Receptor 1 Antibody Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Tachykinin Receptor 1 Antibody Key Players Headquarters & Area Served
- 4.4 Global Tachykinin Receptor 1 Antibody Players, Product Type & Application
- 4.5 Global Tachykinin Receptor 1 Antibody Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Tachykinin Receptor 1 Antibody Market CR5 and HHI
- 4.6.3 2025 Tachykinin Receptor 1 Antibody Tier 1, Tier 2, and Tier 3
5 Tachykinin Receptor 1 Antibody Market Size by Type
- 5.1 Global Tachykinin Receptor 1 Antibody Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Tachykinin Receptor 1 Antibody Revenue by Type (2021-2032)
- 5.3 Global Tachykinin Receptor 1 Antibody Revenue Market Share by Type (2021-2032)
6 Tachykinin Receptor 1 Antibody Market Size by Application
- 6.1 Global Tachykinin Receptor 1 Antibody Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Tachykinin Receptor 1 Antibody Revenue by Application (2021-2032)
- 6.3 Global Tachykinin Receptor 1 Antibody Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Merck
- 7.1.1 Merck Company Information
- 7.1.2 Merck Business Overview
- 7.1.3 Merck Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
- 7.1.4 Merck Tachykinin Receptor 1 Antibody Product Portfolio
- 7.1.5 Merck Recent Developments
- 7.2 Boster Biological Technology
- 7.2.1 Boster Biological Technology Company Information
- 7.2.2 Boster Biological Technology Business Overview
- 7.2.3 Boster Biological Technology Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
- 7.2.4 Boster Biological Technology Tachykinin Receptor 1 Antibody Product Portfolio
- 7.2.5 Boster Biological Technology Recent Developments
- 7.3 United States Biological
- 7.3.1 United States Biological Company Information
- 7.3.2 United States Biological Business Overview
- 7.3.3 United States Biological Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
- 7.3.4 United States Biological Tachykinin Receptor 1 Antibody Product Portfolio
- 7.3.5 United States Biological Recent Developments
- 7.4 Santa Cruz Biotechnology
- 7.4.1 Santa Cruz Biotechnology Company Information
- 7.4.2 Santa Cruz Biotechnology Business Overview
- 7.4.3 Santa Cruz Biotechnology Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
- 7.4.4 Santa Cruz Biotechnology Tachykinin Receptor 1 Antibody Product Portfolio
- 7.4.5 Santa Cruz Biotechnology Recent Developments
- 7.5 Proteintech
- 7.5.1 Proteintech Company Information
- 7.5.2 Proteintech Business Overview
- 7.5.3 Proteintech Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
- 7.5.4 Proteintech Tachykinin Receptor 1 Antibody Product Portfolio
- 7.5.5 Proteintech Recent Developments
- 7.6 ProSci
- 7.6.1 ProSci Company Information
- 7.6.2 ProSci Business Overview
- 7.6.3 ProSci Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
- 7.6.4 ProSci Tachykinin Receptor 1 Antibody Product Portfolio
- 7.6.5 ProSci Recent Developments
- 7.7 NSJ Bioreagents
- 7.7.1 NSJ Bioreagents Company Information
- 7.7.2 NSJ Bioreagents Business Overview
- 7.7.3 NSJ Bioreagents Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
- 7.7.4 NSJ Bioreagents Tachykinin Receptor 1 Antibody Product Portfolio
- 7.7.5 NSJ Bioreagents Recent Developments
- 7.8 LSBio
- 7.8.1 LSBio Company Information
- 7.8.2 LSBio Business Overview
- 7.8.3 LSBio Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
- 7.8.4 LSBio Tachykinin Receptor 1 Antibody Product Portfolio
- 7.8.5 LSBio Recent Developments
- 7.9 GeneTex
- 7.9.1 GeneTex Company Information
- 7.9.2 GeneTex Business Overview
- 7.9.3 GeneTex Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
- 7.9.4 GeneTex Tachykinin Receptor 1 Antibody Product Portfolio
- 7.9.5 GeneTex Recent Developments
- 7.10 FineTest
- 7.10.1 FineTest Company Information
- 7.10.2 FineTest Business Overview
- 7.10.3 FineTest Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
- 7.10.4 FineTest Tachykinin Receptor 1 Antibody Product Portfolio
- 7.10.5 FineTest Recent Developments
- 7.11 Everest Biotech
- 7.11.1 Everest Biotech Company Information
- 7.11.2 Everest Biotech Business Overview
- 7.11.3 Everest Biotech Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
- 7.11.4 Everest Biotech Tachykinin Receptor 1 Antibody Product Portfolio
- 7.11.5 Everest Biotech Recent Developments
- 7.12 Cusabio
- 7.12.1 Cusabio Company Information
- 7.12.2 Cusabio Business Overview
- 7.12.3 Cusabio Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
- 7.12.4 Cusabio Tachykinin Receptor 1 Antibody Product Portfolio
- 7.12.5 Cusabio Recent Developments
- 7.13 Atlas Antibodies
- 7.13.1 Atlas Antibodies Company Information
- 7.13.2 Atlas Antibodies Business Overview
- 7.13.3 Atlas Antibodies Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
- 7.13.4 Atlas Antibodies Tachykinin Receptor 1 Antibody Product Portfolio
- 7.13.5 Atlas Antibodies Recent Developments
- 7.14 Advanced Targeting Solutions
- 7.14.1 Advanced Targeting Solutions Company Information
- 7.14.2 Advanced Targeting Solutions Business Overview
- 7.14.3 Advanced Targeting Solutions Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
- 7.14.4 Advanced Targeting Solutions Tachykinin Receptor 1 Antibody Product Portfolio
- 7.14.5 Advanced Targeting Solutions Recent Developments
8 North America
- 8.1 North America Tachykinin Receptor 1 Antibody Revenue (2021-2032)
- 8.2 North America Tachykinin Receptor 1 Antibody Revenue by Type (2021-2032)
- 8.2.1 North America Tachykinin Receptor 1 Antibody Revenue by Type (2021-2026)
- 8.2.2 North America Tachykinin Receptor 1 Antibody Revenue by Type (2027-2032)
- 8.3 North America Tachykinin Receptor 1 Antibody Revenue Share by Type (2021-2032)
- 8.4 North America Tachykinin Receptor 1 Antibody Revenue by Application (2021-2032)
- 8.4.1 North America Tachykinin Receptor 1 Antibody Revenue by Application (2021-2026)
- 8.4.2 North America Tachykinin Receptor 1 Antibody Revenue by Application (2027-2032)
- 8.5 North America Tachykinin Receptor 1 Antibody Revenue Share by Application (2021-2032)
- 8.6 North America Tachykinin Receptor 1 Antibody Revenue by Country
- 8.6.1 North America Tachykinin Receptor 1 Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Tachykinin Receptor 1 Antibody Revenue by Country (2021-2026)
- 8.6.3 North America Tachykinin Receptor 1 Antibody Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
9 Europe
- 9.1 Europe Tachykinin Receptor 1 Antibody Revenue (2021-2032)
- 9.2 Europe Tachykinin Receptor 1 Antibody Revenue by Type (2021-2032)
- 9.2.1 Europe Tachykinin Receptor 1 Antibody Revenue by Type (2021-2026)
- 9.2.2 Europe Tachykinin Receptor 1 Antibody Revenue by Type (2027-2032)
- 9.3 Europe Tachykinin Receptor 1 Antibody Revenue Share by Type (2021-2032)
- 9.4 Europe Tachykinin Receptor 1 Antibody Revenue by Application (2021-2032)
- 9.4.1 Europe Tachykinin Receptor 1 Antibody Revenue by Application (2021-2026)
- 9.4.2 Europe Tachykinin Receptor 1 Antibody Revenue by Application (2027-2032)
- 9.5 Europe Tachykinin Receptor 1 Antibody Revenue Share by Application (2021-2032)
- 9.6 Europe Tachykinin Receptor 1 Antibody Revenue by Country
- 9.6.1 Europe Tachykinin Receptor 1 Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Tachykinin Receptor 1 Antibody Revenue by Country (2021-2026)
- 9.6.3 Europe Tachykinin Receptor 1 Antibody Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
10 China
- 10.1 China Tachykinin Receptor 1 Antibody Revenue (2021-2032)
- 10.2 China Tachykinin Receptor 1 Antibody Revenue by Type (2021-2032)
- 10.2.1 China Tachykinin Receptor 1 Antibody Revenue by Type (2021-2026)
- 10.2.2 China Tachykinin Receptor 1 Antibody Revenue by Type (2027-2032)
- 10.3 China Tachykinin Receptor 1 Antibody Revenue Share by Type (2021-2032)
- 10.4 China Tachykinin Receptor 1 Antibody Revenue by Application (2021-2032)
- 10.4.1 China Tachykinin Receptor 1 Antibody Revenue by Application (2021-2026)
- 10.4.2 China Tachykinin Receptor 1 Antibody Revenue by Application (2027-2032)
- 10.5 China Tachykinin Receptor 1 Antibody Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Tachykinin Receptor 1 Antibody Revenue (2021-2032)
- 11.2 Asia Tachykinin Receptor 1 Antibody Revenue by Type (2021-2032)
- 11.2.1 Asia Tachykinin Receptor 1 Antibody Revenue by Type (2021-2026)
- 11.2.2 Asia Tachykinin Receptor 1 Antibody Revenue by Type (2027-2032)
- 11.3 Asia Tachykinin Receptor 1 Antibody Revenue Share by Type (2021-2032)
- 11.4 Asia Tachykinin Receptor 1 Antibody Revenue by Application (2021-2032)
- 11.4.1 Asia Tachykinin Receptor 1 Antibody Revenue by Application (2021-2026)
- 11.4.2 Asia Tachykinin Receptor 1 Antibody Revenue by Application (2027-2032)
- 11.5 Asia Tachykinin Receptor 1 Antibody Revenue Share by Application (2021-2032)
- 11.6 Asia Tachykinin Receptor 1 Antibody Revenue by Country
- 11.6.1 Asia Tachykinin Receptor 1 Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Tachykinin Receptor 1 Antibody Revenue by Country (2021-2026)
- 11.6.3 Asia Tachykinin Receptor 1 Antibody Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Tachykinin Receptor 1 Antibody Revenue (2021-2032)
- 12.2 SAMEA Tachykinin Receptor 1 Antibody Revenue by Type (2021-2032)
- 12.2.1 SAMEA Tachykinin Receptor 1 Antibody Revenue by Type (2021-2026)
- 12.2.2 SAMEA Tachykinin Receptor 1 Antibody Revenue by Type (2027-2032)
- 12.3 SAMEA Tachykinin Receptor 1 Antibody Revenue Share by Type (2021-2032)
- 12.4 SAMEA Tachykinin Receptor 1 Antibody Revenue by Application (2021-2032)
- 12.4.1 SAMEA Tachykinin Receptor 1 Antibody Revenue by Application (2021-2026)
- 12.4.2 SAMEA Tachykinin Receptor 1 Antibody Revenue by Application (2027-2032)
- 12.5 SAMEA Tachykinin Receptor 1 Antibody Revenue Share by Application (2021-2032)
- 12.6 SAMEA Tachykinin Receptor 1 Antibody Revenue by Country
- 12.6.1 SAMEA Tachykinin Receptor 1 Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Tachykinin Receptor 1 Antibody Revenue by Country (2021-2026)
- 12.6.3 SAMEA Tachykinin Receptor 1 Antibody Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst